EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, JAGX: Jaguar Health Inc

24 Oct 25 15:59
LAST:

2.051

CHANGE:
 0.11		OPEN:
1.990		HIGH:
2.086		ASK:
0.171		VOLUME:
19.9K
CHG(%):
5.53		PREV:
1.990		LOW:
1.935		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 251.9902.1001.9352.10023.2K
23 Oct 251.8701.9901.8701.99031.5K
22 Oct 252.0302.0591.7701.890175.7K
21 Oct 252.2102.2101.9501.990140.3K
20 Oct 252.1002.2002.1002.20020.6K
17 Oct 252.1002.2042.0102.08083.1K
16 Oct 252.2602.3002.0502.120117.8K
15 Oct 252.1302.4002.1102.270205.4K
14 Oct 252.1032.1562.0802.13090.9K
13 Oct 252.0702.1522.0152.13040.6K

COMPANY PROFILE

Name:Jaguar Health Inc
About:Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:200 Pine Street, San Francisco, CA, United States, 94104
Website:https://jaguar.health
CUSIP:47010C409
CIK:0001585608
ISIN:US47010C6075
FIGI:BBG005Z20406

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.06 
Forward P/E:-0.83 
EPS Ratio:37.53 
Price to Book:0.60 
Price to Sales:0.40 
Shares:3.71M 
Market Cap:7.6M 

TECHNICAL INDICATORS

MA5:2.030.8%
MA10:2.091.9%
MA20:2.144.4%
MA50:1.992.9%
MA100:2.3313.5%
MA200:3.0247.2%
STO9:41.18
STO14:40.00
RSI14:46.98
WPR14:-48.78
MTM14:-0.03
ROC14:-0.01 
ATR:0.20 
Week High:2.217.8%
Week Low:1.7715.9%
Month High:2.4419.0%
Month Low:1.7747.2%
Year High:15.48654.8%
Year Low:0.20946.4%
Volatility:51.31 

RECENT SPLITS

Date Ratio
24 Mar 20251-25
23 May 20241-60
23 Jan 20231-75
08 Sep 20211-3
07 Jun 20191-70
01 Jun 20181-15